Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump
- Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity
- 2024 Karnofsky Award winner Lillian Siu talks about her career in phase I studies, ctDNA, and her mentor’s “evil red pencil”
- Biotech companies, investors pour billions into mRNA vaccines as research ramps up in cancer and non-communicable diseases